Glycaemic outcomes in people living with diabetes under 65 and over 65 years old using an intermittently scanned continuous glucose monitoring system.

IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Therapeutic Advances in Endocrinology and Metabolism Pub Date : 2024-08-20 eCollection Date: 2024-01-01 DOI:10.1177/20420188241269133
Carol Wong, Anne De Bray, Naeem Ul Hassan, Ahmed Almohandes, Kyi Zin Thant, Sofia Gill, Dayna Gill, Hayley Forsdick, Alan J Sinclair, Muhammad Ali Karamat, Srikanth Bellary
{"title":"Glycaemic outcomes in people living with diabetes under 65 and over 65 years old using an intermittently scanned continuous glucose monitoring system.","authors":"Carol Wong, Anne De Bray, Naeem Ul Hassan, Ahmed Almohandes, Kyi Zin Thant, Sofia Gill, Dayna Gill, Hayley Forsdick, Alan J Sinclair, Muhammad Ali Karamat, Srikanth Bellary","doi":"10.1177/20420188241269133","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Intermittently scanned continuous glucose monitoring (isCGM) has revolutionised the care of people with diabetes but its uptake and benefits in older adults are not well known. We examined the impact of isCGM (Freestyle Libre, FSL) on glycaemic outcomes in younger (⩽65 years) and older adults (>65 years) with diabetes.</p><p><strong>Design and methods: </strong>In total, 2260 adult patients registered on the Libreview account at University Hospitals Birmingham NHS Foundation Trust, UK, were included. Inclusion criteria: all patients with type 1 and type 2 diabetes aged >18 years, use of isCGM >6 months, scanning at least 6 times/day. Demographics, diabetes history and glycaemic outcomes (time in range (TIR), time above range and time below range (TBR), estimated HbA1c, HbA1c at start and at end of study) were collected by accessing electronic patient records and Libreview. Outcomes were compared between age groups ⩽65 or >65 years old.</p><p><strong>Results: </strong>Most patients were of Caucasian ethnicity (⩽65 years 68%, >65 years 73%) and had type 1 diabetes. Mean duration of diabetes was 19.5 years (range 0-65 years) and 34.5 years (range 0-79 years) for ⩽65 and >65 years, respectively. Only a quarter of those ⩽65 years achieved (219/943; 23.2%) their age specific TIR target compared to 69% (78/113) of those >65 years cohort, while 70.1% (663/946) of ⩽65 years and 40.7% (46/113) of >65 years achieved their age-specific TBR target. When the less strict ⩽65 years TBR target was applied, 75% (85/113) of >65 years cohort achieved this.</p><p><strong>Conclusion: </strong>FSL use was associated with improved glycaemic outcomes across all age groups. Individualised targets may be needed to improve TBR in those aged >65 years.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11337186/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Endocrinology and Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420188241269133","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Intermittently scanned continuous glucose monitoring (isCGM) has revolutionised the care of people with diabetes but its uptake and benefits in older adults are not well known. We examined the impact of isCGM (Freestyle Libre, FSL) on glycaemic outcomes in younger (⩽65 years) and older adults (>65 years) with diabetes.

Design and methods: In total, 2260 adult patients registered on the Libreview account at University Hospitals Birmingham NHS Foundation Trust, UK, were included. Inclusion criteria: all patients with type 1 and type 2 diabetes aged >18 years, use of isCGM >6 months, scanning at least 6 times/day. Demographics, diabetes history and glycaemic outcomes (time in range (TIR), time above range and time below range (TBR), estimated HbA1c, HbA1c at start and at end of study) were collected by accessing electronic patient records and Libreview. Outcomes were compared between age groups ⩽65 or >65 years old.

Results: Most patients were of Caucasian ethnicity (⩽65 years 68%, >65 years 73%) and had type 1 diabetes. Mean duration of diabetes was 19.5 years (range 0-65 years) and 34.5 years (range 0-79 years) for ⩽65 and >65 years, respectively. Only a quarter of those ⩽65 years achieved (219/943; 23.2%) their age specific TIR target compared to 69% (78/113) of those >65 years cohort, while 70.1% (663/946) of ⩽65 years and 40.7% (46/113) of >65 years achieved their age-specific TBR target. When the less strict ⩽65 years TBR target was applied, 75% (85/113) of >65 years cohort achieved this.

Conclusion: FSL use was associated with improved glycaemic outcomes across all age groups. Individualised targets may be needed to improve TBR in those aged >65 years.

65 岁以下和 65 岁以上糖尿病患者使用间歇性扫描连续血糖监测系统的血糖结果。
目的:间歇扫描连续血糖监测(isCGM)为糖尿病患者的护理带来了革命性的变化,但其在老年人中的使用率和益处还不为人所知。我们研究了isCGM(Freestyle Libre,FSL)对年轻(⩽65 岁)和老年(>65 岁)糖尿病患者血糖结果的影响:共纳入 2260 名在英国伯明翰大学医院 NHS 基金会信托基金会的 Libreview 账户上注册的成年患者。纳入标准:所有年龄大于 18 岁的 1 型和 2 型糖尿病患者,使用 isCGM 超过 6 个月,每天至少扫描 6 次。通过访问电子病历和 Libreview 收集人口统计学、糖尿病史和血糖结果(在范围内的时间 (TIR)、高于范围的时间和低于范围的时间 (TBR)、估计 HbA1c、研究开始和结束时的 HbA1c)。对年龄在 65 岁以下或 65 岁以上的患者的结果进行了比较:大多数患者为白种人(68% ⩽65岁,73% >65岁),患有1型糖尿病。⩽65岁和>65岁患者的平均糖尿病病程分别为19.5年(0-65岁)和34.5年(0-79岁)。在 65 岁以上的人群中,只有四分之一(219/943;23.2%)的人达到了年龄特定的 TIR 目标,而在 65 岁以上的人群中,则有 69% (78/113)的人达到了年龄特定的 TBR 目标,而在⩽65 岁和 >65 岁的人群中,分别有 70.1% (663/946)和 40.7% (46/113)的人达到了年龄特定的 TBR 目标。如果采用不太严格的⩽65 岁 TBR 目标,75%(85/113)的 >65 岁组群达到了这一目标:结论:在所有年龄组中,FSL 的使用都与血糖结果的改善有关。要改善年龄大于 65 岁人群的 TBR,可能需要制定个性化目标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutic Advances in Endocrinology and Metabolism
Therapeutic Advances in Endocrinology and Metabolism Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
7.70
自引率
2.60%
发文量
42
审稿时长
8 weeks
期刊介绍: Therapeutic Advances in Endocrinology and Metabolism delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of endocrinology and metabolism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信